Navigation Links
Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
Date:6/19/2008

ion for which mucus build up and clearance is a daily problem. Our bronchiectasis program follows closely behind our work in cystic fibrosis where a phase 3 clinical trial is expected to soon close recruitment.''

Pharmaxis is developing Bronchitol as a treatment to improve mucus clearance in the lungs of patients with cystic fibrosis, bronchiectasis and other acute and chronic pulmonary conditions. The U.S. FDA has granted Bronchitol fast track status and it is designated as an orphan drug in the U.S.

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

CONTACT:

Alan Robertson

Chief Executive Officer

Tel: +61-2-9454-7200

Email: alan.robertson@pharmaxis.com.au

Released through:

United States:

Brandon Lewis, Trout Group

Tel: +1-646-378-2915

Email: blewis@troutgro
'/>"/>

SOURCE Pharmaxis Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmaxis Establishes Named Patient Program for Bronchitol
2. Pharmaxis Long-Term Safety Study of Bronchitol Completes
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
5. Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women
6. Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
9. Most Back Pain Could Be Cured Without Surgery or Drugs if Doctors Treated Muscles - Not the Spine - Says Leading Pain Specialist
10. Specialized Genasense(R) Clinical Trials Featured at AACR Meeting
11. Associated Foot & Ankle Specialists Enrolling Patients With Chronic Diabetic Foot Ulcers for MATRIX Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... WASHINGTON , Sept. 22, 2014 ... deadline of Monday, Sept. 29 at 5 p.m. ... for Kids!" competition, in response to continued strong ... of $50,000 each will be awarded to the ... Pediatric Surgical Innovation Symposium hosted by Children,s National ...
(Date:9/22/2014)... 22, 2014  Elusys Therapeutics, Inc. (Elusys), a ... disease, today announced it has completed three phase ... (ETI-204). Obiltoxaximab is an anti-toxin in development for ... these studies support the safety and tolerability of ... intended therapeutic dose. The conclusion of these studies ...
(Date:9/22/2014)... , Sept. 22, 2014  Continua and ... in healthcare technology, media and telecommunications,  have formed ... China and promote international ... BHG announced this new partnership during the global ... Washington, DC , while also ...
Breaking Medicine Technology:Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 2Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 2Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 3Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 4
... There are some two dozen oncology therapies in Phase ... development. While only some of these therapies will make it ... a competitive marketplace where success revolves around planning as much ... in the oncology therapeutic area must constantly evaluate which factors ...
... April 20, 2012 A recent clinical trial conducted at ... drug used to treat Parkinson,s Disease greatly improves the quality ... such as tremors, slowness, stiffness and difficulty walking. ... hold the trial, which was led by Dr. C. Warren ...
Cached Medicine Technology:Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector 2Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinson's Disease 2Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinson's Disease 3
(Date:9/22/2014)... 2014 As concerns about the ... morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) in gynecological surgeries mount, ... the continued use of uterine morcellation by some ... discouraged these procedures. According to The Wall Street ... risks associated with power morcellators are overblown, and ...
(Date:9/22/2014)... CareFlight Air & Mobile Services ... new AS365 N3+ Dauphin, the latest version of Airbus ... is based at Miami Valley Hospital in ... medical transport helicopters. , “We have a lot of ... Vice President, Emergency, Trauma, and CareFlight. “We’ve been operating ...
(Date:9/22/2014)... 2014 PCI (Project Concern International) ... equip women around the world with tools and training ... Women Empowered (WE) Initiative announced at the CGI Annual ... to pool their savings, invest in their own businesses, ... to ending poverty in the world, and through our ...
(Date:9/22/2014)... NY (PRWEB) September 22, 2014 The ... the Department of Surgery at the Icahn School of ... Doctors New York Group for Plastic Surgery gives residents ... access to a team of world-renowned plastic surgeons performing ... C. Andrew Salzberg, MD, who led NYGPS, was named ...
(Date:9/22/2014)... WHO: LiveOps, Inc., the global ... solutions. , WHAT: The 10th annual Customer Response ... for the connected consumer. Constant change in technology ... challenges and opportunities for customer experience executives. The ... practices, network and learn from fellow attendees, speakers ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 3Health News:PCI Announces New Effort to Empower 250,000 Women Worldwide at 2014 Clinton Global Initiative (CGI) Annual Meeting 2Health News:PCI Announces New Effort to Empower 250,000 Women Worldwide at 2014 Clinton Global Initiative (CGI) Annual Meeting 3Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2
... CLARA, Calif., January 8 Align Technology,Inc. (Nasdaq: ... that the,Company will report fourth quarter and fiscal year ... close of market. Financial results will,be released over PR ... the,Investor Relations section of the Company,s website at, http://investor.aligntech.com ...
... TEAC America, Inc. launches its,next generation P-55C dye-sublimation ... available, during the CES Show at,the Las Vegas Convention ... The P-55C printer can be integrated with 3 TEAC ... With TEAC,s,AL220S and AL550S, customers can print up to ...
... Vyvanse as the Clinical Gold Standard, According to ... 8 Decision Resources, one of the world,s ... and healthcare issues, finds that physicians indicate there ... effective nonstimulant therapy approved for adult attention-deficit/hyperactivity disorder ...
... (Nasdaq: GHDX ) today announced the appointment ... president and chief operating officer,Popovits is now the president ... Cole has been appointed as chief operating officer and ... reporting to Popovits. , "Kim,s ...
... and FirstDoc (Documentum) Solutions Deliver Regulatory Document Management ... CSC (NYSE: CSC ) announced today ... content management (ECM) solutions, adding features designed to ... the document life cycle and the growing collaboration ...
... will force hospitals to reconsider or defer purchases ... GroupWALTHAM, Mass., Jan. 8 According to Millennium ... RIS, and CVIS 2009 report, the budgetary ... affect the markets for picture archiving and communication ...
Cached Medicine News:Health News:Align Technology to Announce Fourth Quarter and Fiscal Year 2008 Results on January 28, 2009 2Health News:TEAC America Launches its Next Generation P-55C Printer, World's Fastest Dye-Sublimation Disc Printer 2Health News:Physicians Express Continued Need for Safe and Effective Nonstimulant Therapies in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder 2Health News:Physicians Express Continued Need for Safe and Effective Nonstimulant Therapies in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder 3Health News:Genomic Health Announces Management Changes and New Responsibilities 2Health News:Genomic Health Announces Management Changes and New Responsibilities 3Health News:Genomic Health Announces Management Changes and New Responsibilities 4Health News:CSC Announces New Releases of Enterprise Content Management Solutions for Life Sciences Industry 2Health News:CSC Announces New Releases of Enterprise Content Management Solutions for Life Sciences Industry 3Health News:Budgetary Constraints on Health Care Facilities to Affect PACS, RIS, and CVIS Markets 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: